Document Detail

Current therapy for dysgerminoma of the ovary.
MedLine Citation:
PMID:  3299187     Owner:  NLM     Status:  MEDLINE    
It is important that therapy of ovarian dysgerminoma be optimized because of the young age of women affected and the threat that therapy may pose to fertility. Our understanding of dysgerminoma has improved, so that treatment schemes with better therapeutic ratio may now be used. Approximately 65% of patients present with stage IA disease. For those wishing to preserve fertility, conservative surgery with close clinical, radiologic, and serologic follow-up is the treatment of choice, with chemotherapy for relapse. Cure rates should approach 100%, and fertility is usually preserved. Intra-abdominal relapse in those not wishing to preserve fertility should be treated with modest-dose pelvic and abdominal irradiation. For those patients with disease presenting in stages IB, II, and III who wish to maintain fertility, unilateral oophorectomy followed by combination chemotherapy may be curative and spare ovarian function. Otherwise, complete surgery, followed by abdominopelvic radiation therapy, is recommended. This treatment produces less morbidity than chemotherapy and will cure approximately two-thirds of patients. Chemotherapy should be used for salvage of subsequent relapse. Both radiation and chemotherapy are highly effective treatment modalities for dysgerminoma. This information, coupled with better understanding of the patterns of disease spread and improved ability to identify nondysgerminomatous elements using serum tumor markers, means that a more conservative approach can be taken to management without compromising the chance of cure. Cure rates for dysgerminoma should now approach the role of 97% achieved in the comparable tumor, testicular seminoma.
G M Thomas; A J Dembo; N F Hacker; A D DePetrillo
Related Documents :
17188887 - Should intraperitoneal chemotherapy be considered as standard first-line treatment in a...
21073707 - Racial differences in treatment and survival in older patients with diffuse large b-cel...
2731767 - Second-look laparotomy in ovarian carcinoma patients after 8 and after 12 courses of ci...
21399857 - Recognition and treatment of bcg failure in bladder cancer.
7693327 - Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant int...
10930477 - Clinical presentation of mucin-secreting tumors of the pancreas.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  70     ISSN:  0029-7844     ISO Abbreviation:  Obstet Gynecol     Publication Date:  1987 Aug 
Date Detail:
Created Date:  1987-08-19     Completed Date:  1987-08-19     Revised Date:  2009-10-26    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  268-75     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Combined Modality Therapy
Dysgerminoma / pathology,  therapy*
Neoplasm Recurrence, Local / therapy
Neoplasm Staging
Ovarian Neoplasms / pathology,  therapy*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Normal fetal heart axis and position.
Next Document:  Pseudophakic keratoplasty: posterior chamber lens implantation in the presence of ruptured capsule.